> MEDIA   Overview   Press Releases   Media Stories   Download Center   Video Gallery   Photo Gallery   Media Contacts

Press Releases 2017 2018 2019 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005     December 2017 29 Dec Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs 13 Dec Company Statement : Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee.” Biocon has paid Facility Fee for its API facility to USFDA in Sep 2017 01 Dec U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers 01 Dec European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim   November 2017 23 Nov Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India 20 Nov Company Statement : Biocon's Drug Product Facility Receives EIR with VAI status, Inspection Closed 07 Nov Company Statement on Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA   October 2017 26 Oct Biocon Q2FY18 Press Release 25 Oct Biocon Ranked Among Top 10 Global Pharma & Biotech Employers 10 Oct Company Statement : US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim 06 Oct Company Statement : No Separate Audit or Observations by Health Canada   September 2017 18 Sept Biocon's Facility in Vishakhapatnam completes US FDA Inspection with no observations 07 Sept Biocon´s Insulins facility in Malaysia Receives EU GMP Compliance Certificate 06 Sept JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment   August 2017 30 Aug USFDA Target Action Date for Trastuzumab Reset to December 3, 2017 16 Aug Company Statement on Status of EMA Dossiers 03 Aug Company Statement on USFDA Visit in May/June2017. CAPA is under Implementation   July 2017 27 Jul Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore, Net Profit at Rs 81 Crore 14 Jul FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab 09 Jul Biocon Statement on ANSM Inspection Report   June 2017 11 Jun Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions 05 Jun Biocon Appoints Ms. Pratima Rao as Mission Director of Biocon Foundation   May 2017 10 May Company Statement on Media Reports on USFDA 483s 05 May Kiran Mazumdar-Shaw Felicitated with 'AWSM Award for Excellence 2017' by The Feinstein Institute for Medical Research, USA   April 2017 27 Apr  Biocon Q4 FY17 Revenue Rs 974 Cr; Net  Profit Rs 127 Cr; FY17 Revenue at Rs 4,079  Cr; Net Profit at Rs 612 Cr   February 2017 16 Feb  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Pegfilgrastim for Review 07 Feb  Biocon Foundation & Department of Medical,  Health & Family Welfare, Govt. of Karnataka  Collaborate to Set Up Smart eLAJ Clinics in  Karnataka   January 2017 25 Jan  Biocon Wins MYR 300 Million Contract for  Insulin from MoH, Malaysia 24 Jan  Biocon Q3 FY17 Net Profit Up 65% at Rs 171  Crore Revenue Rises 32% at Rs 1092  Crore; EBITDA Increases 57% to Rs 324  Crore 11 Jan  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Trastuzumab

Biocon Businesses Recommended sites Biocon on     Home About Us Investor Relations Media Relations Careers Site Map Contact Us Our Growth Accelerators Fact Sheet Branded Formulations Biopharmaceuticals Research Services Active Discovery Program ABLE Karnataka Vision Group on BT Syngene International Biocon Academy                   Report adverse event/side effects and product complaints               * Disclaimer            © 2018, Biocon. All Rights Reserved